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Abstract: This paper briefly reports the occurrence and epidemiology of carbapenem-resistant
but cephalosporin-susceptible (Car-R/Ceph-S) Pseudomonas aeruginosa isolates from urinary tract
infections (UTIs) in a tertiary-care hospital in the Southern Region of Hungary, and the phenotypic
characterization of the possible resistance mechanisms in these isolates. Isolates and data were collected
regarding P. aeruginosa UTIs corresponding to the period between 2008 and 2017. Susceptibility testing
was performed using the Kirby–Bauer disk diffusion method; minimum inhibitory concentrations
(MICs) of the isolates were determined using E-tests. The phenotypic detection of ampicillin
C-type (AmpC) β-lactamases, efflux pump overexpression and carbapenemase production was
also performed. P. aeruginosa represented n = 575 (2.72% ± 0.64%) from outpatient, and n = 1045
(5.43% ± 0.81%) from inpatient urinary samples, respectively. Based on the disk diffusion test, n
= 359 (22.16%) were carbapenem-resistant; in addition to carbapenems, n = (64.34%) were also
resistant to ciprofloxacin; n = (60.17%) to gentamicin/tobramycin; n = (58.51%) to levofloxacin; and
n = (27.57%) to amikacin. From among the carbapenem-resistant isolates, n = 56 (15.59%) isolates
were multidrug-resistant, while n = 16 (4.46%) were extensively drug-resistant. From among the
Car-R/Ceph-S isolates (n = 57), overexpression of AmpC was observed in n = 7 cases (12.28%);
carbapenemase production in n = 4 (7.02%); while overexpression of efflux pumps was present
in n = 31 (54.39%) isolates. To spare last-resort agents, e.g., colistin, the use of broad-spectrum
cephalosporins or safe, alternative agents should be considered in these infections.
Keywords: Pseudomonas aeruginosa; urinary tract infection; carbapenem; cephalosporin; resistance;
uncommon phenotype; phenotypic; efflux pump; ampicillin C (AmpC)
1. Introduction
The emergence of drug resistance in Gram-negative bacteria is an increasingly severe public health
issue, limiting the therapeutic armamentarium of clinicians [1,2]. From the standpoint of antimicrobial
resistance (AMR), non-fermenting Gram-negative bacteria (NFGNB) are especially problematic due to
the many intrinsic and acquired resistance mechanisms they possess or can acquire [3,4]. In addition,
these pathogens are extremely adaptable to biologically unfavorable conditions, e.g., in harsh hospital
environments; thus, they may become a source of opportunistic, nosocomial infections [5]. Urinary
tract infections (UTIs) are the second most common infectious pathologies in developed countries,
corresponding to an important economic and disease burden [6,7]. Previously, the treatment of urinary
tract infections was relatively straightforward due to the predictable pathogen profile and resistance
characteristics; however, with the emergence of AMR and the increasing number of elderly patients
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with underlying illnesses or immunosuppression, the treatment of UTIs is increasingly challenging in
everyday clinical practice [8,9]. There is a growing appreciation for the clinical relevance of NFGNB
in UTIs; among other organisms, the etiological role of P. aeruginosa has been highlighted by several
studies worldwide, especially in debilitated patients or catheterized individuals [10,11]. Pseudomonas
infections may be treated by utilizing β-lactams, fluoroquinolones, aminoglycosides and, in cases of
extensive resistance, ceftolozan/tazobactam and colistin remain as unattractive (due to toxic adverse
events or economic considerations), but viable, therapeutic alternatives [12]. β-lactam antibiotics may
be considered as the backbone of antibiotic therapy, especially in vulnerable patient populations (e.g.,
children, pregnant women, the elderly) [13]. For P. aeruginosa, ceftazidime, cefepime (third and fourth
generation cephalosporins, respectively) and carbapenems (imipenem, meropenem and doripenem)
are relevant therapeutic choices [14]. Nevertheless, resistance in Pseudomonas to β-lactams may be
due to a plethora of different resistance mechanisms: chromosomal production of ampicillin C-type
(AmpC) β-lactamases, acquired cephalosporinases or carbapenemases, overexpression of efflux pumps,
modifications in the penicillin-binding proteins (PBPs) and downregulation or absence of the OprD
porin (i.e., porin mutants) [3,15]. Carbapenemase enzymes have the broadest spectrum of substrates
(from penicillins to carbapenemases); they may eliminate β-lactam antibiotics as viable therapeutic
options, depending on their substrate-profile. However, these enzymes are very diverse with variable
spectra of activity and phenotypic expression levels [16,17]. Several studies have noted the occurrence
of carbapenem-resistant but cephalosporin-susceptible (Car-R/Ceph-S) P. aerugonisa [14,18,19]. In these
strains, the AmpC production is thought to be moderate or low, which would allow for the use
of relevant cephalosporins, instead of other, more toxic agents with a disadvantageous side effect
profile [20]. The aim of the present study was to investigate the occurrence and epidemiology of
Car-R/Ceph-S P. aeruginosa isolates in a tertiary-care hospital in the Southern Region of Hungary,
in addition to the phenotypic characterization of the possible resistance mechanisms in these isolates.
2. Results and Discussion
2.1. Epidemiology and Antibiotic Susceptibility of Car-R/Ceph-S P. aerugonisa from UTIs
Between 2008 and 2017, n = 21,150 positive urine samples were received from outpatient clinics
and n = 19,325 from inpatient departments. Among clinically significant pathogens overall, P. aeruginosa
represented n = 575 (2.72% ± 0.64%) from outpatient, and n = 1045 (5.43% ± 0.81%) from inpatient
samples, respectively (resulting in a sum of n = 1620 samples). Based on the disk diffusion test, n
= 359 (22.16%) were carbapenem-resistant (Car-R, imipenem or meropenem minimum inhibitory
concentration (MIC) ≥ 8 mg/L; n = 80 were imipenem-resistant and 96.25% were also resistant to
meropenem in outpatient samples, while n = 279 were imipenem-resistant and 91.39% were also
resistant to meropenem in outpatient samples, respectively; p = 0.016). The distribution of Car-R
isolates was calculated from clinical samples taken from the following: first-stream urine: n = (2.22%);
midstream urine: n = (27.57%); and catheter-specimen urine: n = (70.21%). The median age of patients
affected by Car-R UTIs was 62 years (range: 0–90 years), with a female-to-male ratio of 0.59 (37.33%
females); the majority of patients (59.71%) were aged 65 years or older. Some 22.28% of the isolates
originated from outpatient clinics, while 56.69% came from the Intensive Care Departments (ICUs),
15.54% from the Dept. of Internal Medicine, and 5.49% from the Dept. of Traumatology.
In addition to carbapenems, n = 231 (64.34%) were also resistant to ciprofloxacin; n = 216
(60.17%) to gentamicin and tobramycin; n = 210 (58.51%) to levofloxacin; and n = 99 (27.57%) to
amikacin, respectively. No colistin resistance was found among Car-R isolates. Resistance levels
were significantly higher in inpatient isolates for ciprofloxacin (p = 0.031); levofloxacin (p = 0.04); and
gentamicin/tobramycin (p = 0.038). From among the Car-R isolates, n = 56 (15.59%) isolates were
multidrug-resistant (MDR), while n = 16 (4.46%) were extensively drug-resistant (XDR).
Car-R/Ceph-S isolates were detected in n = 57 [100%] cases (n = 21 [36.84%] from outpatient
samples and n = 36 [63.16%] from inpatients, respectively; p = 0.041). All isolates (100%) were
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ceftazidime-susceptible (100%; MIC ≤ 8 mg/L), while n = 43 (75.43%) isolates were cefepime-susceptible
(MIC ≤ 8 mg/L). The MIC50 and MIC90 values of imipenem, meropenem, ceftazidime and cefepime
were 16 and 64 mg/L; 8 and 32 mg/L; 2 and 8 mg/L; and 8 and 32 mg/L, respectively.
2.2. Phenotypic Characterization of Resistance Determinants in Car-R/Ceph-S P. aerugonisa Isolates
From among the Car-R/Ceph-S isolates (n = 57), overexpression of AmpC was observed in n = 7
(12.28%) cases (5 from inpatient samples, 2 from outpatient samples), exclusively in isolates that were
susceptible to ceftazidime, but resistant to cefepime. A notable decrease in the ceftazidime MICs was
seen in the presence of cloxacillin. The modified Hodge test was positive (indicating the presence of a
carbapenemase) for n = 4 (7.02%) P. aeruginosa isolates.
Based on the phenotypic assay utilized in our study, overexpression of efflux pumps was present in
n = 31 (54.39%) cases (25 from inpatient samples, 6 from outpatient samples). In n = 22 isolates (38.59%),
decreases in the MICs in the presence of PAβN were observed for both imipenem and meropenem,
while in n = 7 isolates (12.28%), the MIC decreased for imipenem, and in n = 2 cases, for meropenem only.
Simultaneous occurrence of AmpC overexpression and efflux pump overexpression was shown in n =
5 (8.77%) cases, while simultaneous carbapenemase overexpression and efflux pump overexpression
was detected in n = 2 (3.51%) isolates. No resistance determinants could be phenotypically verified in
n = 15 (26.31%) isolates.
2.3. Discussion and Literature Review
P. aeruginosa is one of the most common opportunistic pathogens in hospital-acquired infections,
associated with significant morbidity and mortality in the affected patients, especially in cases of
infections caused by MDR/XDR isolates [21]. The aim of the present study was to demonstrate the
occurrence of Car-R/Ceph-S P. aeruginosa from urinary tract infections over a 10-year surveillance
period in a tertiary-care hospital in Hungary. During the study period, 57 such isolates were detected
(corresponding to an average of 5–6 isolates/year), including 7 isolates with overexpression of AmpC
β-lactamases, 4 isolates producing carbapenemase enzymes and 31 isolates with overexpressed efflux
pumps, based on the phenotypic detection methods utilized. Efflux pump overexpression was shown
to be the most common mechanism of resistance detected in this study, in addition to seven isolates
where efflux pumps and β-lactamases were present simultaneously. No conclusive data could be
obtained for the resistance determinants in fifteen isolates. Although it may be assumed that porin
downregulation or deletion may be the underlying mechanism of resistance in these cases, no results
from phenotypic or genotypic assays corroborate this hypothesis.
P. aeruginosa, as a urinary pathogen, has received substantial attention in recent years, which
may be attributed to its increased prevalence in catheter-associated infections of hospitalized and/or
immunocompromised patients [10,22]. In addition, recent studies have highlighted the most important
virulence factors associated with P. aeruginosa in catheter-associated infections [23]. Epidemiological
reports are scarce in this field; however, most studies available conclude that there is a significantly
higher risk for inpatients and that debilitated patients older than 65 years of age are the most
affected [23,24]. Over a three-year period, Ferreiro et al. recorded n = 62 nosocomial UTIs, with an
overall 30-day mortality rate of 17.7% [24]. A Japanese study group reported 76 patients (n = 59 male
and n = 17 female) with a P. aeruginosa UTI infection over a four-year period [25]. In a study from
India, the prevalence of NFGNB (including P. aeruginosa) in UTIs was <2% [26]. As part of a national
prospective surveillance study for nosocomial infections in ICUs in France, Venier et al. reported n =
525 (16% overall) P. aeruginosa UTIs; in addition, they identified male sex, previous antibiotic therapy,
hospital admission and transfer from another ICU as individual risk factors [27]. Finally, in a study
from Israel, Marcus et al. identified n = 28 (8% overall) community-acquired P. aeruginosa UTIs in
children [28].
There are very few studies available in the literature reporting on the phenomenon of Car-R/Ceph-S
P. aeruginosa, and most of these publications originate from the Far East. A Chinese study consisting
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of Car-R/Ceph-S P. aeruginosa collected between July and October 2011 found n = 29 individual
isolates [19]. In this study, the authors demonstrated that decreased expression or deletion of the
OprD porins was the most common mechanism of resistance (using Western blotting and RT-PCR),
while production of carbapenemase or Ambler class C β-lactamase enzymes was not observed in these
isolates. In another study by Chinese authors, P. aeruginosa isolates from bacteremic patients between
2010 and 2017 showing the Car-R/Ceph-S phenotype were assessed [29]: during the eight-year period,
n = 63 isolates were detected and most of the microorganisms showed efflux pumo-overexpression
and decreased expression of OprD. Similar to the previous study, production of relevant β-lactamase
enzymes was not noted. In this report, the overall 30-day mortality rate of affected patients was also
assessed, and was shown to be 27.0% [29]. In a Korean study, n = 18 ceftazidime-susceptible isolates
were found in 77 imipenem-resistant P. aeruginosa samples [30]. In their report, thirteen isolates showed
overexpression of the efflux pump genes mexB, mexD, mexF and mexY, and two isolates presented
with ampC gene overexpression; all Car-R/Ceph-S isolates showed a significant decrease in oprD gene
expression. All of the eighteen isolates were resistant to cefepime [30]. Khuntayaporn et al. described
the characterization of n = 293 P. aeruginosa isolates collected between 2007 and 2009 [15]. Decreased
oprD gene expression was observed in the majority of isolates (>93%), in addition to overexpression of
efflux pumps in around two thirds (63.5%) of the isolates. Metallo-β-lactamase production and AmpC
β-lactamase hyperproduction showed a lower prevalence (18.5% and 3.9%, respectively) [15]. A study
from Brazil, spanning the years 2012 and 2013, reported n = 25 individual P. aeruginosa isolates from
all clinical sample types [18]. Most of these bacteria had reduced oprD gene expression levels, while
AmpC hyperproduction, carbapenem hydrolysis (detected by the MALDI-TOF MS method) and efflux
pump overexpression (RT-PCR) were not shown in these isolates. A recently published clinical study
from Israel (corresponding to the time period between 2010 and 2014) reported n = 67 monobacterial
Car-R/Ceph-S bloodstream infections (mainly associated with UTIs and pneumonia), where the authors
highlighted that cephalosporins were relevant therapeutic options for these infections [31]. In addition,
a study from Iran identified n = 23 Car-R/Ceph-S P. aeruginosa isolates from 243 clinical samples, from
the time period between 2016 and 2018 [14]. From among the 23 Car-R/Ceph-S samples, none of the
isolates were positive for carbapenemase genes. Overexpression of AmpC was detected in n = 1 (4.3%)
isolate. The phenotypic assay for overexpressed efflux pumps was positive in n = 14 (60.9%) isolates,
while overexpression of relevant efflux pumps was shown in 47.3%–68.8% (depending on the efflux
pump) by RT-PCR [14].
Carbapenems may be considered as the last line of safe therapeutic alternatives in many
infections; however, carbapenem resistance is on the rise, both in NFGNB and in the members
of the Enterobacterales order [11,16,32,33]. While in the latter group, Car-R is predominantly caused
by the acquisition of plasmid-encoded carbapenemases, in NFGNB (including Pseudomonas spp.), there
are several possible resistance mechanisms at play, including degrading enzymes, modifications in
the transpeptidases, porin deletion and the overexpression of efflux transporters [2–4,10,12,14,19,34].
In addition, Pseudomonas species are members of the “SPACE” (Serratia spp., Pseudomonas spp.,
Acinetobacter spp., Citrobacter spp., Enterobacter spp.) organisms, characterized by inducible AmpC-based
resistance [20,35]. Although the overlap between these resistance mechanisms may be significant,
cases of Car-R/Ceph-S may be identified where the use of cephalosporins instead of colistin may
be warranted [36]. Colistin is currently considered a last-resort, life-saving antibiotic for resistant
Gram-negative infections [37]. Irrespective of its disadvantagous adverse effects and difficult dosing,
based on pharmaco-epidemiological studies, the use of this agent is on the rise [38]. Nevertheless, its
increased use will undeniably lead to increased resistance levels to this drug, as this phenomenon has
been demonstrated for many other anti-pseudomonal antibiotics [39]. Car-R/Ceph-S isolates present
an opportunity for microbiological/diagnostic stewardship, and a viable target for colistin-sparing
stewardship interventions [40]. Although colistin resistance in P. aeruginosa is still relatively rare
(especially in countries limiting the use of this agent), nevertheless, a steady increase in the resistance
levels for colistin may be expected in the coming years [41]. Similar to the findings of other
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reports [14,18,19], resistance levels to other antibiotics were also pronounced, with ~60% resistance to
fluoroquinolones and gentamicin.
Limitations of the present study include the lack of molecular biological methods used to further
characterize resistance determinants in the detected isolates, e.g., for the detection of various bla genes
(blaNDM, blaKPC, blaOXA-48, and blaVIM, among others), and the detection of the overexpression of
efflux pump genes (mexAB, mexCD, mexXY) or the reduced expression of the oprD porin compared
to a housekeeping gene [14]. The prevalence of metallo-β-lactamase enzymes in Car-R P. aeruginosa
isolates may be wide-ranging, based on literature findings (2%–100%) [42]. However, the hypothesis of
Khalili et al. states that the occurrence of Car-R/Ceph-S isolates is due to the absence of carbapenemases,
leading to the susceptible phenotype for ceftazidime and cefepime [14]. This may point to the relevance
of OprD porin mutation as a substantial mechanism of resistance solely for carbapenems [15]. Although
there are only a few studies available, the proportion of strains with reduced OprD expression or lack
of OprD was very high (100% [19]; 100% [30]; 93.85% [15]; >90% [29]; 78.26% [14], and 41.38% [18],
respectively). The role of OprD mutation in carbapenem resistance has been highlighted in repeated
exposure to carbapenems [14,15,43]. In addition, this study was limited to isolates from UTI infections,
while other studies included P. aeruginosa isolates from various clinical samples. Nevertheless,
the present report is still relevant.
3. Materials and Methods
3.1. Study Design and Data Collection
The present study was carried out using isolates and collected data, corresponding to the time
period between January 1, 2008 and December 31, 2017, at the Institute of Clinical Microbiology,
University of Szeged (Szeged, Hungary). The Institute serves as the dedicated microbiology laboratory
of the Albert Szent-Györgyi Clinical Center, which is a 1820-bed primary- and tertiary-care teaching
hospital, affiliated with the University of Szeged [44]. Data collection was performed electronically
by searching the records of the laboratory information system (LIS) for urine samples positive for P.
aeruginosa, based on the criteria below.
Samples with clinically significant colony counts for P. aeruginosa (>105 CFU/mL) that were positive
for nitrite and leukocyte-esterase tests were included; however, this was subject to interpretation
by senior clinical microbiologists performing identification and reporting, based on the information
provided on the clinical request forms for the microbiological analysis and international guidelines [10].
Only the first isolate per patient was included in the study; however, isolates with different antibiotic
susceptibility patterns from the same patient were considered as different individual isolates. To
evaluate the demographic characteristics of these infections, patient data, limited to sex, age at sample
submission, and inpatient/outpatient status, were also collected [10].
3.2. Identification of P. aeruginosa Isolates
Some 10 µL of each uncentrifuged urine sample was cultured on UriSelect chromogenic agar
(Bio-Rad, Berkeley, CA, USA) and blood agar (bioMérieux, Marcy-l’Étoile, Lyon, France) plates
with a calibrated loop, according to the manufacturer’s instructions, and incubated at 37 ◦C for
24–48 h, aerobically. In the period between 2008 and 2012, presumptive, biochemical reaction-based
methods and VITEK 2 Compact ID/AST (bioMérieux, Marcy-l’Étoile, France) were used for bacterial
identification. From 2013 onward, MALDI-TOF MS (Bruker Daltonik Gmbh., Billerica, MA, USA) was
introduced into the workflow of the Department of Bacteriology. Mass spectrometry was performed
using a Microflex MALDI Biotyper (Bruker Daltonics, Bremen, Germany) instrument, with MALDI
Biotyper RTC 3.1 software (Bruker Daltonics, Bremen, Germany), and the MALDI Biotyper Library
3.1 for the spectrum analysis. The sample preparation, methodology, and the technical details of the
MALDI-TOF MS measurements are described elsewhere [9,10].
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3.3. Antibiotic Susceptibility Testing and Determination of the Minimum Inhibitory Concentrations (MICs)
Antimicrobial susceptibility testing was performed using the Kirby–Bauer disk diffusion method
(Liofilchem, Abruzzo, Italy) on Mueller–Hinton agar (MHA) plates for ceftazidime, cefepime, imipenem,
meropenem, ciprofloxacin, levofloxacin, gentamicin, tobramycin and amikacin. MICs of the isolates
were determined using E-tests (Liofilchem, Abruzzo, Italy) on MHA plates for ceftazidime, cefepime,
imipenem, and meropenem. In addition, for the verification of discrepant results, the broth
microdilution method in a cation-adjusted Mueller–Hinton broth (MERLIN Diagnostika, Bonn,
Germany) was also utilized. Colistin susceptibility was performed using the broth microdilution
method in a cation-adjusted Mueller–Hinton broth (MERLIN Diagnostik). The interpretation of the
results was based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
breakpoints [45]. Car-R/Ceph-S P. aeruginosa was defined as isolates resistant to carbapenems (imipenem
or meropenem), but susceptible to cephalosporins (ceftazidime or cefepime) [14]. Staphylococcus aureus
ATCC 29213, Enterococcus faecalis ATCC 29212, Proteus mirabilis ATCC 35659, Escherichia coli ATCC
25922, P. aeruginosa ATCC 27853 and Acinetobacter baumannii ATCC 19606 were used as quality control
strains. Intermediate (I) susceptibility results were not observed during the study. Classification of the
isolates as multidrug-resistant (MDR) or extensively drug-resistant (XDR) was based on the EUCAST
Expert Rules [46].
3.4. Phenotypic Detection of AmpC Overexpression and Carbapenemase Production
Overexpression of AmpC β-lactamase enzymes was detected by an agar plate method, where the
agar base was supplemented with cloxacillin (250 µg/mL), as cloxacillin inhibits the effects of AmpC
β-lactamases. A two-fold decrease in ceftazidime MICs in the presence of cloxacillin, compared to
MICs without cloxacillin, was considered as positivity for AmpC overexpression [14,47]. Phenotypic
screening for carbapenemase production was detected by the modified Hodge (cloverleaf) test,
optimized for P. aerugniosa, as previously described [39,48].
3.5. Phenotypic Detection of Efflux Pumps
The effect of phenylalanine-arginine β-naphthylamide (PAβN; a compound with well-known
efflux pump inhibitory activity) on the MICs of imipenem and meropenem was detected using the agar
dilution method described previously [14,47]. During the experiments, the concentration of PAβN was
40 µg/mL in the agar base. A two-fold decrease in the MICs in the presence of PAβN, compared to the
MIC values without the inhibitor, was considered as positivity for efflux pumpoverexpression [14,49,50].
3.6. Statistical Anaylsis
Statistical analyses, including the descriptive analysis (means or medians with ranges and
percentages to characterize data) and statistical tests (Student’s t-test (for data on resistance levels))
were performed with the SPSS software version 24 (IBM SPSS Statistics for Windows 24.0, IBM Corp.,
Armonk, NY, USA); p-values < 0.05 were considered statistically significant.
4. Conclusions
The main objective of the present study was the epidemiological assessment and phenotypic
characterization of Car-R/Ceph-S P. aeruginosa isolates in a tertiary-care hospital in Szeged, Hungary.
As a result, n = 56 Car-R/Ceph-S P. aeruginosa isolates were identified as part of a 10-year surveillance.
During the study, overexpression of efflux pumps and overexpression of AmpC enzymes were identified
as the main mechanisms of resistance. To spare last-resort agents in relevant clinical situations, the use
of broad-spectrum cephalosporins or safe, alternative agents should be considered in these infections
to curb the development of extended selection pressure on non-fermenting Gram-negative bacteria, a
group of pathogens where the emergence of extensively drug-resistant and pandrug-resistant clinical
strains is a frightening reality.
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